UNSPSC 51351915: Quingestanol acetate

This classification denotes a norpregnadiene C27H36O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M33GGZ63KG, chemically known as 3-(cyclopentyloxy)-19-nor-17.alpha.-pregna-3,5-dien-20-yn-17-ol acetate, but more generally known as quingestanol acetate, which bears US NIH Compound Identifier 18142. European Medicines Agency schedules Quingestanol acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04165MIG.

Most nations, for tariff and trade purposes, schedule quingestanol acetate under HS 29372300 and SITC 54153. As of Q4 2014, QUINGESTANOL ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@H]3CCC(=C4)OC5CCCC5)C)C#C.

UNSPSC 51351915 Quingestanol acetate is a Commodity code capturing pharmaceutical products being procured through state and local cooperative purchasing vehicles for distribution to government facilities. The work entails supplying generic multi-source pharmaceuticals and over-the-counter products meeting cGMP and Drug Supply Chain Security Act compliance standards, with vendors required to maintain relationships with authorized wholesalers, submit detailed product data including National Drug Codes and packaging specifications, and offer flexible pricing structures ranging from flat-price to WAC-minus formats. Issuing bodies under this code include state procurement offices and multistate cooperative purchasing alliances administering centralized pharmaceutical contracts on behalf of participating state agencies, local government facilities, and other member entities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent activity, with a cooperative structure designed to serve multiple participating jurisdictions across states including Oregon.

MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. Vendors must demonstrate compliance with current Good Manufacturing Practices, maintain contractual relationships with at least two of three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and carry comprehensive insurance including $5 million commercial general liability per occurrence. Evaluation weights 75 percent price competitiveness, 10 percent fixed pricing for the contract term, and 5 percent each for administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. Awards will be effective July 1, 2026, with a contract term of two years for new vendors and optional extensions at MMCAP's discretion, while incumbent vendors' amendments align with existing expiration dates through June 30, 2028.